A Moody’s Downgrade Could Punish Mallinckrodt
As sales of blockbuster drug Acthar begins to crack Mallinckrodt (MNK) is in desperate need of a new narrative. Management is trying to sell investors on the idea that it can generate new products from its R&D pipeline. In the meantime it is also looking to diversify its revenue and earnings stream via acquisition. Last…